

# COMPARATIVE CLINICAL EFFICACY STUDY BETWEEN ERENUMAB AND FREMANEZUMAB

Fresquet R<sub>1</sub>, Sopena L<sub>1</sub>, Vinuesa JM<sub>1</sub>, Merchan A<sub>1</sub>, Cazorla L<sub>1</sub>, Perez M<sub>1</sub>, Frutos A<sub>1</sub>, Arenere M<sub>1</sub>, Pardo MP<sub>1</sub>, Allende MA<sub>1</sub>, Salvador T<sub>1</sub> Pharmacy Department. Hospital Clínico Universitario Lozano Blesa. Zaragoza. Spain

## AIM

Compare the efficacy of monoclonal antibody drugs against the calcitonin gene-related peptide pathway in migraine and to establish whether they can be considered equivalent therapeutic alternatives in this pathology.

## METHODS


**Retrospective observational** study patients with chronic migraine with the next treatment for at least 6 months:

- 21 patients on treatment with Fremanezumab 225mg/30 days
- 24 patients on treatment with Erenumab 70mg/30 days.

Data were collected at baseline and six months on the following Scales:

- Headache Impact Test (HIT)
- Migraine Disability Assessment Scale (MIDAS)
- Pain intensity numerical scale: 0 (no pain) and 10 (unbearable pain).
- Days of migraine per month.

## RESULTS



HIT in both cases decreased more than 6 points (efficacy criterion). MIDAS in both drugs decreased by more than 30% (efficacy endpoint). For erenumab and fremanezumab, >50% reduction was observed (efficacy endpoint).

## CONCLUSION

The initial values of the scales are very similar. The initial situation of the patient is not a trigger for the use of one or the other.

Clinically there is no difference between the two drugs.